Syntimmune, Inc.

Johnson & Johnson is looking to both take a lead position in a burgeoning area of the autoimmune therapy space and bolster its presence in the Boston-area biotech hub with its planned $6.5bn acquisit

The health care- and technology-focused venture capital firm Polaris Partners – an active investor in biopharmaceutical companies – disclosed in a filing with the US Securities and Exchange Commission

Alexion Pharmaceuticals Inc. is continuing to search out potential novel therapies in the complement and rare diseases spaces, areas it knows well, with the latest candidates expected to come from co

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Alexion Teams With Dicerna O